Industry Overview - The Medical sector is experiencing a continued recovery in sales, with earnings increasing year over year by 4.7% on 9.4% higher revenues, although inflationary pressures and supply chain challenges persist [1][2] - The first-quarter earnings for the Medical sector are expected to improve by 35%, while sales are projected to increase by 7.8%, compared to the previous quarter's earnings growth of 13.4% and revenue growth of 9.4% [3] Medical Device Industry Insights - The medical device industry began 2025 with robust growth, driven by sustained demand for advanced healthcare solutions and the normalization of elective procedures, with the global market projected to reach $1.3 trillion by 2029 [4] - Challenges such as semiconductor shortages and workforce shortages in AI and robotics are impacting production and innovation [5] - Trade tensions, particularly U.S.-China tariffs, have increased operational costs for medical device manufacturers, with 75% of U.S.-marketed medical devices manufactured abroad [6] Company Performance Expectations - Becton Dickinson is expected to report strong second-quarter results, with a projected revenue growth of 16.3% year over year in its Medical division, although a slight dip of 1.3% is anticipated in the Life Sciences segment [8] - Cardinal Health is expected to show steady performance in its Pharmaceutical and Specialty Solutions segment, supported by strategic acquisitions, despite the impact of a key customer contract expiration [10] - Baxter International is projected to report moderate growth, with an estimated 6.6% sales growth in its Medical Products & Therapies segment, aided by operational recovery [11] - DexCom's outlook remains promising, with a full-year revenue guidance of $4.6 billion, driven by expanded U.S. prescriber coverage and strong international performance [12] - Stryker Corporation is expected to show strong growth across multiple segments, with projected U.S. and international sales reaching $4.74 billion and $1.59 billion, respectively [13]

Core Insights - ONWARD Medical N.V. has filed its Annual Report for the fiscal year ended December 31, 2024, with the Dutch Authority for the Financial Markets (AFM) [1] - The company has also released its 2024 Sustainability Report and received a silver medal from EcoVadis for business sustainability ratings [2] - CEO Dave Marver highlighted that 2024 was transformative for ONWARD, emphasizing the company's mission to restore movement and independence for individuals with spinal cord injuries [2] Company Overview - ONWARD Medical is focused on creating therapies aimed at restoring movement, function, and independence for people with spinal cord injuries and other movement disabilities [3] - The company has developed ARC Therapy, which has received ten Breakthrough Device Designations from the US FDA, and its ARC-EX System is cleared for commercial sale in the US [3] - ONWARD is also working on an investigational implantable system called ARC-IM, which may include a brain-computer interface [3] Locations and Listings - The company is headquartered in the Netherlands, with a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts [4] - ONWARD Medical is listed on Euronext Paris, Brussels, and Amsterdam under the ticker ONWD, and its US ADRs can be traded on OTCQX under the ticker ONWRY [4]

Core Insights - Integer Holdings Corporation reported a strong start to 2025 with a 7% year-over-year sales growth and a 14% increase in adjusted operating income [1][5] - The company raised its adjusted net income growth outlook to a range of 19% to 26% for 2025, while maintaining a sales growth forecast of 8% to 10% [1][4] Financial Performance - First quarter 2025 sales reached $437 million, up from $407.8 million in the same period last year, reflecting a 7% increase [5][18] - GAAP operating income increased by 28% to $50 million, while non-GAAP adjusted operating income rose by 14% to $71 million [5][37] - GAAP income from continuing operations showed a loss of $22 million, a decrease from a profit of $20.6 million in Q1 2024, primarily due to debt conversion inducement expenses [5][37] - Non-GAAP adjusted net income increased by 19% to $46 million, with adjusted EPS rising to $1.31 from $1.14 [5][41] Product Line Performance - Cardio & Vascular sales increased by 17% year-over-year, driven by new product launches and acquisitions [6] - Cardiac Rhythm Management & Neuromodulation sales grew by 2%, supported by emerging neuromodulation customers [6] - Other Markets sales decreased by 37%, primarily due to the planned exit from the Portable Medical market [6][18] 2025 Outlook - The company updated its 2025 outlook to reflect the impact of a $1 billion convertible note offering, which is expected to reduce interest expenses by $13 million [3][5] - Adjusted operating income for 2025 is projected to be between $331 million and $401 million, reflecting an 11% to 16% increase [4][5] - The leverage ratio as of March 28, 2025, was reported at 3.3 times adjusted EBITDA, with total debt increasing to $1.235 billion [5][12] Leadership Changes - The company announced that Joseph Dziedzic will retire as President and CEO on October 24, 2025, with Payman Khales set to assume the role [20]

Core Insights - Neuronetics, Inc. plans to release its first quarter 2025 financial and operating results on May 6, 2025, prior to market open [1] - A conference call will be held at 8:30 a.m. Eastern Time on the same day to discuss the results [1][2] Company Overview - Neuronetics, Inc. focuses on improving the quality of life for patients with neurohealth disorders through innovative medical technology [3] - The company is a leader in neuroscience, offering the NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for mental health conditions [3] - NeuroStar is indicated for treating depressive episodes and reducing anxiety symptoms in adults with Major Depressive Disorder (MDD) who have not responded to previous antidepressant treatments [3] - The therapy is also FDA-cleared for use as an adjunct treatment for adults with obsessive-compulsive disorder and for adolescents aged 15-21 with MDD [3] - Over 7.1 million NeuroStar treatments have been delivered, establishing it as the leading Transcranial Magnetic Stimulation (TMS) treatment for MDD in adults [3]

Core Points - Enovis Corporation announced the appointment of Damien McDonald as CEO, effective May 12, 2025, succeeding Matt Trerotola who will retire [1][3] - The company expects first quarter revenues to be between $555 million and $563 million, with adjusted EBITDA projected to be between $97 million and $100 million [1][6] Leadership Transition - Sharon Wienbar, Lead Independent Director, expressed enthusiasm for McDonald's appointment, highlighting his strong track record in the medical technology sector [2] - McDonald has over 35 years of experience in the medical device industry, previously serving as CEO of LivaNova, where he improved growth, profitability, and shareholder value [2][3] - Following Trerotola's retirement, Wienbar will assume the role of independent Chair of the Board [3] Company Overview - Enovis Corporation is focused on developing clinically differentiated medical technology solutions aimed at improving patient outcomes [4] - The company emphasizes a culture of continuous improvement and innovation, with a diverse range of products and services in orthopedics and beyond [4]

Core Viewpoint - Polyrizon Ltd. has successfully closed a private placement raising approximately $17.0 million through the sale of Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit [1][3]. Group 1: Offering Details - The offering included the sale of 35,416,667 Ordinary Units, each comprising one Ordinary Share or Pre-Funded Warrant and one Series A Warrant to purchase one Ordinary Share [2]. - The initial exercise price for each Series A Warrant is set at $1.20 per Ordinary Share, with a term of 30 months, and is subject to shareholder approval [2]. - The Pre-Funded Warrants can be exercised at any time following shareholder approval [2]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Company Overview - Polyrizon is a development-stage biotech company focused on innovative intranasal hydrogels that create a barrier against viruses and allergens in the nasal cavity [6]. - The company's proprietary technology, Capture and Contain TM, aims to function as a "biological mask" and is being further developed for drug delivery [6]. - Polyrizon is also working on an earlier-stage technology, Trap and Target ™, for nasal delivery of active pharmaceutical ingredients [6].

Company Appoints Medical Device and Healthcare Industry Veteran with 20 Years of ExperienceEXTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical today announced the appointment of Kevin Kearney as Chief Commercial Officer (CCO). Kearney brings over 20 years of commercial leadership, business development, and strategic sales operations experience in the medical device and healthcare industries. His appointment marks a significant milestone as the company expands its footprint and accelerates its m ...

Company Overview - Aimfinity Investment Corp. I is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands, focused on effecting mergers, share exchanges, asset acquisitions, and similar business combinations with various businesses or entities [3] - The company has not yet selected a business combination target and has not initiated substantive discussions with any potential targets [3] - Aimfinity will not complete its initial business combination with any target headquartered in China or conducting a majority of its business in China [3] Business Combination Update - The company announced an extension of the deadline to complete its initial business combination from February 28, 2025, to March 28, 2025, with a Monthly Extension Payment of $55,823.8, equating to $0.05 per Class A ordinary share held by public shareholders [1][2] - This extension is the second of nine monthly extensions allowed under the company's current charter, which permits monthly extensions from January 28, 2025, until October 28, 2025 [2] Merger Agreement - On October 13, 2023, Aimfinity entered into a Merger Agreement with Docter Inc., proposing a business combination involving a reincorporation merger and an acquisition merger [4] - The press release indicates that further information regarding the proposed business combination will be provided in a proxy statement/prospectus to be mailed to stockholders [4]

Core Insights - Senseonics Holdings, Inc. received FDA approval for the Eversense 365 Continuous Glucose Monitoring (CGM) system and launched it in partnership with Ascensia Diabetes Care, marking a significant advancement in diabetes care [1][3] - The patient base for Eversense increased by 56% in 2024 compared to 2023, reaching approximately 6,000 global patients [1][6] - The company reported total revenue of $8.3 million for Q4 2024, a slight increase from $8.0 million in Q4 2023, with U.S. revenue remaining stable at $6.2 million [4] Financial Performance - Fourth quarter 2024 gross profit was $4.0 million, up from $1.1 million in Q4 2023, primarily due to improved margins on the Eversense 365 product [5] - For the full year 2024, total revenue was $22.5 million, slightly up from $22.4 million in 2023, with U.S. revenue increasing to $15.3 million from $14.1 million [9] - The net loss for Q4 2024 was $15.5 million, a reduction from a net loss of $17.2 million in Q4 2023, attributed to improved gross profit margins [8] Operational Highlights - The Eversense 365 system was launched in the U.S. in 2024, and early performance indicators showed positive results, including record new patient shipments of approximately 600 in December [6] - The company exceeded 2,400 annual U.S. prescribers for Eversense in 2024, with 81% of patients switching from competitive CGMs [6] - Senseonics initiated a collaboration with Mercy Health to study the use of Eversense and remote patient monitoring [6] Future Outlook - For 2025, Senseonics expects global net revenue to be approximately $34-38 million, anticipating a doubling of the global patient base [15] - The company plans to enhance gross margins throughout 2025, projecting margins between 25-30% for the year [15] - Cash utilization in 2025 is expected to be between $50-$60 million as the company continues to roll out Eversense 365 [15]

As filed with the Securities and Exchange Commission on July 23, 2024 Registration No. 333-280525 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioSig Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 3845 26-4333375 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...